> Daktari Diagnostics closed a $15.5 million Series D round to support development of its portable HIV test, reaching a milestone in its goal of raising $30 million in funding. Story
> Exact Sciences ($EXAS) and Ironwood Pharmaceuticals ($IRWD) are teaming up to promote Exact's noninvasive stool DNA screening test for colorectal cancer in the U.S. Statement
> AltheaDx withdrew plans for its previously-announced IPO, citing unattractive market terms. Filing
> LabCorp ($LH) is touting promising study results which show that its HERmark breast cancer test can help distinguish which patients would most benefit from single agent or dual agent therapy. Release
> Pfizer Canada has signed onto Contextual Genomics and the Personalized Medicine Initiative's National Access Project consortium, providing a grant and technical support to help make genomic cancer testing more widely available to Canadian citizens. Statement
> Quest Diagnostics ($DGX) changed the terms of its cash tender offers to purchase up to $250 million instead of $1.2 billion. Release
> Myriad's ($MYGN) RBM subsidiary launched new testing services based on Quanterix's Simoa platform, which allows clinicians to measure difficult-to-detect protein biomarkers in blood samples. Release
> San Diego, CA-based Biocept ($BIOC) rolled out a new companion diagnostic that identifies EGFR mutations through a liquid biopsy in patients with non-small cell lung cancer, helping them find a suitable therapy. Release
> VolitionRx ($VNRX) kicked off a pilot study in Belgium to see how well its NuQ tests detect prostate cancer in patients. More
And Finally… HIV testing has reached an all-time high 30 years after the FDA approved the first commercial blood test for the virus. But more work lies ahead as more than 186,000 individuals with HIV are still undiagnosed, Dr. Jonathan Mermin, director of the CDC's National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, told the Huffington Post. Blog post